The cancer drug developer has closed an initial public offering which took place alongside a $160m SoftBank-led private placement.

The small molecule drug developer has raised a series B round that brought its total funding to more than $100m.

Novartis Venture Fund returned for the small molecule drug developer’s series B round, tipping its total funding to over $100m.

The immuno-oncology drug developer’s prospective initial public offering would mark exits for Takeda, Merck Group, Ipsen and Merck & Co.

The diversified therapeutics developer has filed to go public in the United States a year after Pfizer contributed to its $310m series A round.

UChicago spinout Pyxis Oncology is aiming to raise more than $153m in its initial public offering, having set a price range of $14 to $16.

Sesame Ventures helped lazy eye treatment developer Luminopia raise $12m while UPS, Qualcomm and Mercado Libre exited courier marketplace Mandaê in a purchase by Nuvemshop.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

SoftBank invested $125m through a $160m private placement as portfolio company and cancer drug developer Exscientia went public in an offering sized at nearly $305m.

The Fosun-backed ophthalmology equipment provider raised cash that will go to research, recruitment and commercialisation activities.